Numinus Wellness Inc.

Equities

NUMI

CA67054W1032

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 09:30:00 2024-07-09 am EDT			5-day change	1st Jan Change
0.04 ^CAD	0.00%		-11.11%	-63.64%

Jun. 20	Numinus Wellness Signs Letter of Intent to Buy MedBright AI Investments	MT
Jun. 20	Numinus Wellness Brief: MedBright AI Announcing Strategic Acquisition by Numinus Wellness	MT

Numinus Wellness Inc. Announces Financial Results for the First Quarter Ended November 20, 2020

January 29, 2021 at 04:46 pm EST

Numinus Wellness Inc. announced financial results for the first quarter ended November 20, 2020. For the quarter, Revenue was $229,188 against $134,415 a year ago. Loss and Comprehensive Loss for the Period was $1,928,737 against $911,251 a year ago.

Latest news about Numinus Wellness Inc.

Numinus Wellness Signs Letter of Intent to Buy MedBright AI Investments	Jun. 20	MT
Numinus Wellness Brief: MedBright AI Announcing Strategic Acquisition by Numinus Wellness	Jun. 20	MT
Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board	Jun. 20	CI
Numinus Wellness Inc. executed a letter of intent to acquire MedBright AI Investments Inc. from Michael Dalsin and others for CAD 9.6 million.	Jun. 19	CI
Numinus Wellness Inc. Announces Its Cedar Clinical Research Select for Cybin's Phase 3 Pivotal Multinational Clinical Trial of CYB003	Jun. 08	CI
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD	Jun. 07	CI
Transcript : Numinus Wellness Inc. - Shareholder/Analyst Call	May. 31
Numinus Wellness Secures Health Canada Approval for Study Into Group Model For MDMA-Assisted Therapy	May. 30	MT
Numinus Wellness Brief: Says Received Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy	May. 30	MT
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy	May. 30	CI
Numinus Wellness to Focus on U.S. Operations as it Transitions Out of Canada	May. 07	MT
Numinus Wellness Brief: Announces a strategic plan designed to streamline expenses and "Sharpen" focus on Higher-growth U.S. operations	May. 07	MT
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	Apr. 17	MT
Cybin Selects Numinus Wellness Inc.'s Cedar Clinical Research as clinical research site for Its Phase 3 Study of CYB003	Apr. 17	CI
Transcript : Numinus Wellness Inc., Q2 2024 Earnings Call, Apr 15, 2024	Apr. 15
Numinus Wellness Drops 25% as it Explores Options for its Canadian Operations; FQ2 Profit Falls	Apr. 15	MT
Toronto Stocks Edge Lower; Parkland Shares Up After Rebuffing Call for Strategic Review	Apr. 15	DJ
Numinus Wellness Exploring Options For Canadian Operations; Comes After It Posted QoQ Decrease in Q2 Revenue, Gross Profit	Apr. 15	MT
Numinus Wellness Brief: Co Has decided to Explore Opportunities to "Redefine, divest and/or discontinue" its Canadian clinical operations	Apr. 15	MT
Numinus Wellness Brief: Says To Focus on U.S. operations and Citing "Strategic Adjustments" in its Canadian Market Presence	Apr. 15	MT
Numinus Wellness Posts QoQ Decrease in Q2 Revenue, Gross Profit	Apr. 15	MT
An undisclosed buyer agreed to acquire Canadian clinical operations from Numinus Wellness Inc..	Apr. 14	CI
Numinus Wellness Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 12	CI
PharmAla Biotech Signs Sale Agreement with Numinus Wellness	Mar. 26	MT
Numinus Wellness Submits Clinical Trial Application to Health Canada	Mar. 20	MT

Chart Numinus Wellness Inc.

Duration

Period

More charts

Company Profile

Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.

Sector

Biotechnology & Medical Research

Calendar

2024-11-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Numinus Wellness Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.04

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUMINUS WELLNESS INC.	-63.64%	9.4M
MODERNA, INC.	+17.52%	44.63B
LONZA GROUP AG	+43.57%	40.46B
IQVIA HOLDINGS INC.	-9.12%	38.07B
ALNYLAM PHARMACEUTICALS, INC.	+33.19%	32.27B
CELLTRION, INC.	-8.98%	27.3B
ICON PUBLIC LIMITED COMPANY	+14.60%	26.53B
UNITED THERAPEUTICS CORPORATION	+45.29%	14.06B
MEDPACE HOLDINGS, INC.	+32.54%	12.54B
BIO-TECHNE CORPORATION	-8.64%	11.28B

Other Biotechnology & Medical Research